Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Rating of “Buy” from Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $5.50.

A number of equities analysts have issued reports on IKT shares. Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. LADENBURG THALM/SH SH started coverage on shares of Inhibikase Therapeutics in a report on Wednesday, March 4th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Tuesday, April 21st.

Inhibikase Therapeutics News Summary

Here are the key news stories impacting Inhibikase Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple earnings estimates for Inhibikase Therapeutics, including Q2 2026, Q3 2026, Q4 2026, several 2027 quarters, FY2026, and FY2027. While the company is still expected to post losses, the smaller loss estimates can be viewed as a modestly favorable sign for investor expectations.
• Neutral Sentiment: Short interest data showed no reported short interest as of May 28, with 0 shares outstanding in the report and a days-to-cover ratio of 0.0. This looks more like a data anomaly than a meaningful trading catalyst, so it is unlikely to have much impact on the stock.
• Neutral Sentiment: The earnings estimate comparison article does not appear to introduce any new fundamental development beyond analyst commentary, so it is likely to have limited standalone impact on the share price.

Inhibikase Therapeutics Price Performance

IKT opened at $1.75 on Tuesday. The company has a market capitalization of $231.05 million, a price-to-earnings ratio of -4.07 and a beta of 0.96. The firm’s fifty day moving average price is $1.78 and its two-hundred day moving average price is $1.74. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $2.26.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). As a group, equities analysts anticipate that Inhibikase Therapeutics will post -0.41 EPS for the current year.

Hedge Funds Weigh In On Inhibikase Therapeutics

A number of hedge funds have recently bought and sold shares of IKT. Siren L.L.C. purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter worth about $11,992,000. Squadron Capital Management LLC purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter worth about $8,661,000. Spruce Street Capital LP purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter worth about $7,342,000. ADAR1 Capital Management LLC boosted its holdings in shares of Inhibikase Therapeutics by 53.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock worth $16,531,000 after buying an additional 2,816,346 shares during the last quarter. Finally, Kalehua Capital Management LLC boosted its holdings in shares of Inhibikase Therapeutics by 118.4% in the 1st quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock worth $6,421,000 after buying an additional 2,071,890 shares during the last quarter. 3.81% of the stock is owned by hedge funds and other institutional investors.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.